Refractory asthma

Medical Clinics of North America

Volumn 86, Issue 5, 2002, Pages 1073-1090

  McGeehan, Maureen ^a   Busse, William W ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PREDNISOLONE; PREDNISONE; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST;

ASTHMA; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG INDICATION; DRUG MECHANISM; GASTROESOPHAGEAL REFLUX; HUMAN; META ANALYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; VASCULITIS; VIRUS INFECTION;

ASTHMA; HUMANS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 0036710111     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(02)00034-2     Document Type: Review

References (60)

1. Schwartz HJ, Lowell FC, Melby JC. Steroid resistance in bronchial asthma. Ann Intern Med 1968;69:493-9.
2. Carmichael J, Paterson IC, Diaz P, et al. Corticosteroid resistance in chronic asthma. BMJ 1981;282:1419-22.
3. National Heart Lung and Blood Institute. National Asthma Education and Prevention Program. Exper Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Publ No 97-4051. Bethesda: National Institutes of Health; 1997.
4. Matsuse H, Shimoda T, Matsuo N, et al. Corticosteroid resistance in mild asthma: Markers of persistent inflammation. Ann Allergy Asthma Immunol 1999;82:457-62.
5. Wenzel SE. The phenotypes of severe asthma: Evidence for heterogeneity of the disease. In: Rose BD. editor. Up to Date. Wellesly (MA); 2000.
6. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000;16:432-6.
7. Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000;162:2341-51.
8. Nakase H, Itani T, Mimura J, et al. Relationship between asthma and gastro-oesophageal reflux: Significance of endoscopic grade of reflux oesophagitis in adult asthmatics. J Gastroenterol Hepatol 1999:14:715-22.
9. Bresciani M, Paradis L, Des RA, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol 2001;107:73-80.
10. Loza CC. Severe steroid-dependent asthma with IgG-2 deficiency and recurrent sinusitis: Response to treatment with high-dose intravenous immunoglobulin. Allergol Immunopathol (Madr) 1999;27:165-7.
11. Fletcher D, Mainardi JL, Brun-Buisson C, et al. Cardiac asthma presenting as status asthmaticus: Deleterious effect of epinephrine therapy. Intensive Care Med 1990;16:466-8.
12. Newman KB, Mason III UG, Schmaling KB. Clinical features of vocal cord dysfunction. Am J Respir Crit Care Med 1995;152:1382-6.
13. Harding SM. Gastroesophageal reflux and asthma: Insight into the association. J Allergy Clin Immunol 1999;104:251-9.
14. Roussos C, Macklem PT. The respiratory muscles. N Engl J Med 1982;307:786-97.
15. Slavin RG. Complications of allergic rhinitis: Implications for sinusitis and asthma. J Allergy Clin Immunol 1998;101:S357-60.
16. Maillard I, Schweizer V, Broccard A, et al. Use of botulinum toxin type A to avoid tracheal intubation or tracheostomy in severe paradoxical vocal cord movement. Chest 2000;118:874-7.
17. Barnes PJ, Woolcock AJ, Difficult asthma. Eur Respir J 1998;12:1209-18.
18. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-8.
19. Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996;154:S21-6.
20. Kino T, Chrousos GP. Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes. J Endocrinol 2001;169:437-45.
21. Alvarez J, Surs W, Leung DY, et al. Steroid-resistant asthma: Immunologic and pharmacologic features. J Allergy Clin Immunol 1992;89:714-21.
22. Corrigan CJ, Brown PH, Barnes NC, et al. Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 1991;144:1016-25.
23. Lane SJ, Palmer JB, Skidmore IF, et al. Corticosteroid pharmacokinetics in asthma. Lancet 1990;336:1265.
24. Kamada AK, Szefler SJ. Mechanisms of action of glucocorticoids in asthma and rhinitis. In: Busse WW, Holgate ST, editors. Asthma and Rhinitis. Boston: Blackwell Scientific Publications; 1995. p. 1255-66.
25. Bronnegard M. Steroid receptor number: Individual variation and down-regulation by treatment. Am J Respir Crit Care Med 1996;154:S28-32.
26. Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma: Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994;93:33-9.
27. Adcock IM, Lane SJ, Brown CR, et al. Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol 1995;154:3500-5.
28. Strickland I, Kisich K, Hauk PJ, et al. High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. J Exp Med 2001;193:585-94.
29. Hamid QA, Wenzel SE, Hauk PJ, et al. Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 1999;159:1600-4.
30. Sousa AR, Lane SJ, Soh C, et al. In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation. J Allergy Clin Immunol 1999;104:565-74.
31. Lane SJ, Adcock IM, Richards D, et al. Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. J Clin Invest 1998;102:2156-64.
32. Adcock IM, Nasuhara Y, Stevens DA, et al. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: Preferential targeting of NF-kappa B and lack of I-kappa B involvement. Br J Pharmacol 1999;127:1003-11.
33. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270:286-90.
34. Hart L, Lim S, Adcock I, et al. Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappa B in asthma. Am J Respir Crit Care Med 2000;161:224-31.
35. Adcock IM, Shirasaki H, Gelder CM, et al. The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. Life Sci 1994;55:1147-53.
36. Brostjan C, Anrather J, Csizmadia V, et al. Glucocorticoid-mediated repression of NF kappa B activity in endothelial cells does not involve induction of IkappaBalpha synthesis. J Biol Chem 1996;271:19612-6.
37. Newton R, Hart LA, Stevens DA, et al. Effect of dexamethasone on interleukin-1beta-(IL-1 beta)-induced nuclear factor-kappa B (NF-kappa B) and kappa B-dependent transcription in epithelial cells. Eur J Biochem 1998;254:81-9.
38. Wang Y, Zhang JJ, Dai W, et al. Dexamethasone potently enhances phorbol ester-induced IL-1beta gene expression and nuclear factor NF-kappaB activation. J Immunol 1997;159:534-7.
39. Gern JE, Busse WW. The role of viral infections in the natural history of asthma. J Allergy Clin Immunol 2000;106:201-12.
40. Hahn DL. Chlamydia pneumoniae, asthma, and COPD: What is the evidence? Ann Allergy Asthma Immunol 1999;83:271-88.
41. Hogg JC. Childhood viral infection and the pathogenesis of asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 1999;160:S26-8.
42. Kraft M, Cassell GH, Henson JE, et al. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med 1998;158:998-1001.
43. Leung DY, Cassell GH, Gutierrez J, Martin RJ, Kraft M. T cell responses to Mycoplasma pneumoniae (MP) in patients with chronic asthma [abstract]. J Allergy Clin Immunol 2002;109(1):S26.
44. Matsuse T, Hayashi S, Kuwano K, et al. Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am Rev Respir Dis 1992;146:177-84.
45. Yamada K, Elliott WM, Brattsand R, et al. Molecular mechanisms of decreased steroid responsiveness induced by latent adenoviral infection in allergic lung inflammation. J Allergy Clin Immunol 2002;109:35-42.
46. Aaron SD, Dales RE, Pham B. Management of steroid-dependent asthma with methotrexate: A meta-analysis of randomized clinical trials. Respir Med 1998;92:1059-65.
47. Marin MG. Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: A meta-analysis. Chest 1997;112:29-33.
48. Coffey MJ, Sanders G, Eschenbacher WL, et al. The role of methotrexate in the management of steroid-dependent asthma. Chest 1994;105:117-21.
49. Erzurum SC, Leff JA, Cochran JE, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma: A double-blind, placebo-controlled study. Ann Intern Med 1991;114:353-60.
50. Shiner RJ, Nunn AJ, Chung KF, et al. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990;336:137-40.
51. Nizankowska E, Soja J, Pinis G, et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995;8:1091-9.
52. Salmun LM, Barlan I, Wolf HM, et al. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: A double-blind, placebo-controlled, randomized trial. J Allergy Clin Immunol 1999;103:810-5.
53. Kishiyama JL, Valacer D, Cunningham-Rundles C, et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol 1999;91:126-33.
54. Christian VJ, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000;162:578-85.
55. Lofdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319:87-90.
56. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: A randomised double-blind placebo-controlled trial. Lancet 2001;357:2007-11.
57. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998;279:455-7.
58. D'Cruz DP, Barnes NC, Lockwood CM. Difficult asthma or Churg-Strauss syndrome? BMJ 1999;318:475-6.
59. Tuggey JM, Hosker HS. Churg-Strauss syndrome associated with montelukast therapy. Thorax 2000;55:805-6.
60. Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 2001;164:S12-7.